



**Australian Government**

---

**Department of Health and Ageing**

## **SCHEDULE OF PHARMACEUTICAL BENEFITS FOR DENTAL PRACTITIONERS**

This Schedule is also available on the internet at  
[www.pbs.gov.au](http://www.pbs.gov.au)

### **SUMMARY OF CHANGES**

**EFFECTIVE 1 October 2012**

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <http://www.ag.gov.au/cca>

This Schedule provides information on the arrangements for the prescribing and supply of pharmaceutical benefits. These arrangements operate under the *National Health Act 1953*. However, at the time of printing, the relevant legislation giving authority for the changes included in this issue of the Schedule may still be subject to the usual Parliamentary scrutiny. This book is not a legal document, and, in cases of discrepancy, the legislation will be the source document for payment for the supply of pharmaceutical benefits. The legislation is available from the Federal Register of Legislative Instruments website at <http://www.frli.gov.au>.

The information is not intended to give or replace any legal, medical, dental or optometrical advice. This document is not a legal document and does not constitute legal advice. Neither the information nor this document can be relied upon without first seeking and obtaining independent legal, medical, dental or optometrical advice beforehand. To the extent permitted by law, the Commonwealth of Australia will not be held responsible, nor accept any liability (whether arising out of negligence or otherwise), for any injury, damages, costs, expenses and losses suffered or incurred by a person where such a person has relied on this document or used the information in it as legal, medical, dental or optometrical advice.

# SUMMARY OF CHANGES

## Additions

### Addition – Brand

3301R	<i>Yomax 250, DO</i> – <b>Amoxycillin</b> , Capsule 250 mg
3300Q	<i>Yomax 500, DO</i> – <b>Amoxycillin</b> , Capsule 500 mg

## Deletions

### Deletion – Brand

5046N	<i>Ozcef, RA</i> – <b>Cefaclor</b> , Powder for oral suspension 125 mg per 5 mL, 100 mL
5047P	<i>Ozcef, RA</i> – <b>Cefaclor</b> , Powder for oral suspension 250 mg per 5 mL, 75 mL

## Alterations

### Alteration – Maximum Quantity

		<i>From</i>	<i>To</i>
1832K	<b>Metronidazole</b> , I.V. infusion 500 mg in 100 mL ( <i>DBL Metronidazole Intravenous Infusion</i> )	5	10
5154G	<b>Metronidazole</b> , I.V. infusion 500 mg in 100 mL ( <i>Baxter Healthcare Pty Ltd</i> )	5	10